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ABSTRACT 
The work presented demonstrates the advantage of combining the power of 
evolution to design a scaffold with the implementation of in silico screens to accelerate 
the process of drug discovery and development.  First, a novel stereospecific synthesis is 
developed and utilized to obtain a bioactive compound identified from a fruit used in 
traditional Indian Ayurvedic preparations for the treatment of diabetes.  This compound 
is shown to provide selective and potent inhibition of the disease target aldose 
reductase in vitro.  In addition, β-glucogallin inhibits markers of oxidative stress in 
cellular disease models, as well as sorbitol accumulation under hyperglycemic conditions 
in an ex-vivo lens culture utilizing transgenic mice overexpressing human aldose 
reductase in the lens.  A preliminary computational model to describe the potency of 
aldose reductase inhibitors is developed and suggests that a bioisosteric substitution of an 
amide for the labile ester would improve stability to hydrolysis without affecting potency 
negatively.  Another stereospecific synthesis is developed and implemented to obtain this 
novel compound, N-[(3,4,5-trihydroxy)benzoyl]-β-D-glucopyranosylamine, which is 
found to retain the in vitro potency and selectivity of the parent compound.  Further, a 
marine alkaloid from Xestospongia sp. known to have antitumor activity is shown to have 
increased in vitro potency against the target Topoisomerase IIα in the presence of the 
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activity-enhancing protein Metnase.  The apparent affinity of the enzyme for ATP is 
found to increase linearly with increasing concentrations of neoamphimedine, suggesting 
competitive inhibition, and a computational model is utilized to visualize the possibility 
of neoamphimedine binding within the ATPase site. 
 
The form and content of this abstract are approved. I recommend its publication. 
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β-Glucogallin: A Selective Inhibitor of Human Aldose Reductase Isolated from 
Emblica Officinalis 
Diabetes Mellitus (D.M.) has reached epidemic proportions on a global scale, 
with prevalence expected to rise.  The U.S. spent $245 billion in 2012 to treat D.M. and 
its countless secondary complications, up from $174 billion in 2007. [1]  Diabetic eye 
disease, including cataracts and retinopathy, remains a leading cause of adult blindness in 
the United States.  Surgical measures exist which can slow the progression of cataracts 
and retinopathy; however, these measures are costly and destructive and consequently 
have limited application.  Further complicating the situation, newly diagnosed D.M. 
patients have often already developed retinopathy.  Therefore, finding a therapeutic safe 
enough for chronic dosing is critical for necessary preventative treatment. 
For decades, aldose reductase (AKR1B1, E.C. 1.1.1.21) has been an attractive 
target for such therapy.  Under hyperglycemic conditions, excess glucose is pushed into 
the polyol pathway, shown in Figure 1.1, where it is first reduced to sorbitol and then 
oxidized to fructose by sorbitol dehydrogenase, inducing oxidative stress. [2, 3]  Sorbitol 
has been shown to be highly elevated in animal models of diabetic cataract, and the 
development of diabetic cataracts can be prevented by the administration of aldose 
reductase inhibitors (ARIs). [4]  Though clinical trials for ARIs began in the 1980s, none 
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are currently FDA-approved in the United States, either due to a lack of efficacy or from 
toxicity caused by nonspecific inhibition.   
As ARIs have been pursued for many years, much has been learned about the 
target enzyme’s structure.  AKR1B1 is a member of the aldo-keto reductase (AKR) 
superfamily of enzymes, which reduce a variety of aldehydes using a markedly similar 
active site.  Particular emphasis has been placed on understanding the distinction between 
AKR1B1 and aldehyde reductase (AKR1A1, E.C.1.1.1.2).  Numerous ARIs have been 
demonstrated to have strong potency for AKR1A1, leading to toxicity in preclinical as 
well as clinical development, and so the differences between the active sites of these two 
AKR superfamily members has been studied at length. [5-7]   It is well established that a 
relatively small number of residues comprise a flexible loop near the C-terminus, which 
is an additional 9 residues in length for AKR1A1, that determines substrate and inhibitor 
selectivity.  Site-directed mutagenesis studies proved residues within this C-terminal loop 
to be responsible for the recognition of uncharged substrates by AKR1B1 as well as the 
preference for negatively charged substrates displayed by AKR1A1. [8]  These studies 
Figure 1.1.  The polyol pathway leads to accumulation of sorbitol and fructose 
under hyperglycemic conditions.  This accumulation contributes to oxidative stress, 
leading to diabetic complications like retinopathy and neuropathy.  As the initiator of this 
pathway, aldose reductase has remained a clinical target for treatment and prevention of 
diabetic complications for more than thirty years. 
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suggested the flexibility of this loop, which has been confirmed by structural 
investigations using XRAY crystallography.  This flexibility allows AKR1B1 to 
effectively reduce aldehyde substrates with high affinity across a broad range of small 
molecule aldehydes. [9-11]  The site can accommodate three-carbon substrates like 
methylglyoxal and glyceraldehyde as well as isocorticosteroids with Km values in the low 
µM range, as shown in Figure 1.2.  This accommodative ability can explain how 
numerous ARIs, though demonstrated to bind within the active site, do not displace 
substrates in kinetic experiments and fail to demonstrate competitive inhibition. 
 
Figure 1.2. Published substrate affinities for human AKR1B1.  From left to right, 
20α-isocorticosterone, methylglyoxal, L-glyceraldehyde, and xylose.  Km values were 
taken from literature publications where studies were conducted using the human 
enzyme. [9-11] 
 
Additionally, the flexible active site complicates the analysis of ARIs by affecting 
the enzymatic mechanism of AKR enzymes.  The reaction mechanism as determined by 
steady-state and stopped-flow kinetic experiments is shown in Figure 1.3.  In the forward 
direction (reduction of aldehyde), it is the enzymatic isomerization (E*→E) before 
release of NADP+ (k11) that is found to be the rate-limiting step. [12]  As discussed by 
Bohren and Grimshaw, the observed inhibition pattern for ARIs binding in the active site 
predicted by classical steady-state inhibition theory can fail to be observed in kinetic 
experiments based on the relative contributions of the slope (Kis) and intercept (Kii) 
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component.  The contributions of these components to the observed behavior were shown 
to be dependent upon both the dissociation constant of the relevant inhibitor complex and 
the fraction of total enzyme present in the relevant form during steady-state. 
Our lab had previously isolated and identified an ARI in the lyophilized extracts 
of Emblica officinalis fruits.  E. officinalis, commonly known as Amla in the practice of 
Ayurveda (Indian traditional medicine), has been used for millennia as a treatment for 
diabetes related complications.  Previous work had shown that crude aqueous extracts 
from Amla fruit delayed the onset and progression of cataracts and normalized diabetes-
induced markers such as lipid peroxidation and increased protein oxidation. [13, 14]  
These studies also demonstrated that the active component(s) of the aqueous extract 
penetrate the lens and substantially delay the progression of cataracts through AKR1B1 
inhibition. 
Figure 1.3.  The reaction mechanism of AKR1B1 as determined by steady-state and 
stopped-flow kinetic experiments, including inhibitor complexes.  E is AKR1B1, 
RCHO is xylose, RCH2OH is xylitol, and *E is the isomerized form of the enzyme.  Two 
additional steps have been included to allow for inhibitor (I) binding to *E·NADP+ and 
*E·NADPH, respectively. The binding of NADPH and the release of NADP+ (in the 
direction of aldehyde reduction) induces an enzymatic conformational change that is the 
rate-limiting step of the mechanism.  From Bohren and Grimshaw. [12] 
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The primary active component was identified to 
be the compound 1-O-galloyl-β-D-glucose, better known 
as β-glucogallin, or βgg, shown in Figure 1.4. [15]  This 
surprisingly well-known compound was first synthesized 
in 1918 by Emil Fisher [16], and has since been shown to 
be a key bioprecursor found in numerous plants for 
larger, more complex tannins such as the gallotannins and 
ellagitannins. [17]  However, our ability to analyze the 
activity of this compound was greatly limited by the lack 
of sufficient stock compound, which was isolated by 
semi-preparative HPLC.  We therefore sought to 
synthesize the compound for a more thorough in vitro and 
in vivo analysis of its efficacy as an AKR1B1 inhibitor, in 
the hopes of developing a novel, nontoxic ARI for the prevention and treatment of the 
numerous diabetic complications resulting from chronic hyperglycemia.  The work 
presented here describes the synthesis and characterization of βgg as well as the rational 
design, synthesis and characterization of a hydrolytically stable pharmacophore based on 
the structure of βgg.  Using the rational drug design model developed here, this new 
pharmacophore represents a novel compound that can be readily utilized for preclinical 
drug design to improve efficacy in vitro and in vivo. 
 
  
Figure 1.4. The structure of 
βgg.  This polyphenolic 
glycoside was identified as 
the primary active constituent 
in extracts of E. officinalis 




Neoamphimedine: A Novel Topoisomerase IIα Inhibitor Isolated from 
Xestospongia spp. 
The clinically used anticancer agents etoposide and doxorubicin suffer from drug 
resistance and in many cases cause secondary malignancies after the initial tumor is 
treated.  These compounds are known to exert their antitumor activity by preventing the 
enzyme topoisomerase IIα (TopoIIα) from completing its cell cycle duties. [18, 19]  As 
its name implies, TopoIIα is responsible for relieving topological strain of DNA double 
strands during mitosis, using the hydrolysis of ATP for energy, as shown in Figure 1.5.  
As a result, TopoIIα has an N-terminal homodimeric ATPase domain in addition to its C-
terminal binding domain. [18, 20-22]   
Figure 1.5.  The enzymatic mechanism of TopoIIα DNA ligation and the steps which 
are inhibited by classical TopoIIα inhibitors.  Classical inhibitors bind specific 
TopoIIα conformations within the mechanism.  From Nitiss, J.L. [18] 
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 Classical TopoIIα poisons like etoposide and doxorubicin inhibit enzyme 
function by stabilizing the cleavage complex, i.e. the intermediate complex in which 
TopoIIα is bound to cleaved DNA, by binding the C-terminal domain.  This mechanism 
of inhibition is objectionable for two major reasons: first, TopoIIα functions alone and in 
protein-protein complexes that occlude TopoIIα poison binding sites resulting in drug 
resistance, and second, stabilization of the cleavage complex causes DNA breaks which 
often lead to secondary malignancies.  We reasoned that because TopoIIα needs ATP to 
function, whether with or without protein complex partners, the ATPase sites will remain 
structurally conserved and solvent-accessible when TopoIIα is in complex with other 
proteins such as the Wnt-controlled TCF transcription complex. [23-26] 
Neoamphimedine (Figure 1.6) was first reported as an antineoplastic agent 
identified from extracts of Xestospongia spp., the marine barrel sponges. [27, 28]  Due to 
their excessively long lifetime, little is known about their 
life cycle, but they are known to reproduce asexually in a 
process where a sponge cell detaches from the organism, 
floats away and attaches itself somewhere new and 
generates an entirely new organism mitotically. [29]  This 
process is of particular interest because it is strikingly 
similar to the epithelial-mesenchymal transition (EMT) 
required for cancer metastasis in many human cancers. 
[30-32]  Additionally, Wnt signaling and TCF 
transcription have been shown to be conserved in 
Figure 1.6.  The structure 
of neoamphimedine.  This 
marine alkaloid was 
identified from Xestospongia 




sponges. [33]  Thus, our lab postulates that without endocrine glands, this process may be 
regulated by endogenous small molecules such as neoamphimedine.   
It has been shown that neoamphimedine is as effective as clinical TopoIIα poisons 
in vitro and in vivo, without stabilizing the cleavage complex. [27, 28]  Interactions of 
TopoIIα with protein complex partners such as Metnase have been shown to greatly 
reduce the efficacy of etoposide at inhibiting TopoIIα, so we first sought to explore 
whether this was true for neoamphimedine as well.  The work presented here also 
demonstrates the assessment of the anti-metastatic efficacy of neoamphimedine, which 
has not previously been established.  Additionally, we conducted in vitro kinetic analyses 
and explored the ATPase sites of TopoIIα to assess the validity of our hypothesis that 
neoamphimedine competitively inhibits ATPase activity.   
 
Thesis Statement 
The work presented in this thesis seeks to characterize evolutionarily-designed 
pharmacophores that exert novel inhibitory activity against well-known disease targets 
that can eliminate the adverse effects of traditional preclinically- and clinically-used 
inhibitors.  Combining the power of nature to provide the bioactive scaffold and 









SYNTHESIS AND CHARACTERIZATION OF β-GLUCOGALLIN AS AN 
ALDOSE REDUCTASE INHIBITOR 
 
Synthesis of β-Glucogallin from Gallic Acid 
Background and Rationale 
Work in our lab had previously identified βgg to be a major bioactive constituent 
of E. officinalis extract, through bioassay-guided HPLC fractionation. [15]  In 
preliminary assays, this compound showed great promise both in vitro and ex vivo.  
However, in order to fully characterize its properties, a greater quantity of stock 
compound was needed than could readily be provided by semi-preparative HPLC 
isolation.  A novel stereospecific synthesis was designed and utilized to produce over 200 
mg of the pure natural product, as shown in Figure 2.1. 
 
Figure 2.1. Stereospecific synthetic scheme to yield βgg from gallic acid.  Phenols 
were masked by benzyl protecting groups and removed by catalytic hydrogenation.  The 
C4 and C6 hydroxy groups of glucose were protected using a benzylidene acetal, 




General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Structures were 
confirmed by 1H NMR collected using a Bruker Avance III 400 (400 MHz) and analyzed 
using ACD/NMR Processor software (v 12.01, Advanced Chemistry Development, Inc., 
Toronto, Canada). 
Synthesis of 3,4,5-tris(benzyloxy)benzoic acid (1) and 3,4,5-
tris(benzyloxy)benzoyl chloride (2).  The phenols of gallic acid were masked with benzyl 
ethers using the method of Xie and Zhou [34] modified as follows for the use of benzyl 
chloride.  Gallic acid (10.0 g) was stirred vigorously in dry DMF with a large excess of 
anhydrous K2CO3.  The reaction vessel was heated to 80°C under N2 and excess benzyl 
chloride was added drop-wise over the course of an hour.  Three hours after the 
completion of addition, the reaction was cooled and the excess K2CO3 was filtered.  The 
remaining steps of the procedure were unaltered.  After cooling, the acid was precipitated 
by adjusting the pH to 2 (by pH paper) using concentrated HCl.  The precipitate was 
collected by filtration and recrystallized from methanol to yield pure 1, (19.6 g, 75 %Y).  
The acyl chloride of 1 was prepared by treatment with SOCl2 and used immediately, as 
described previously for 3,4,5-triacetoxybenzoyl chloride without modification. [35] 
Synthesis of 1-O-(3,4,5-tris(benzyloxy)benzoyl)-4,6-O-benzylidene-β-D-
glucopyranose (3).  The enantiomerically pure (β-conformer) sodium salt of 4,6-O-
benzylidene-D-glucopyranose (NaBG) was prepared from glucose using the method of 
Zervas as described by Barili et. al. [36] without modification.  The conjugation reaction 
was performed as previously described for other polyphenolic glycosides. [37]  Briefly, 
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to a suspension of NaBG in freshly distilled dry DCM under N2 was added 0.9 molar 
equivalents 2, also dissolved in DCM.  The mixture was stirred vigorously for 72 hours, 
and then extracted with water.  The organic layer was dried over sodium sulfate and the 
crude product was purified by flash chromatography (silica, EtOAc:CHCl3 1:1, Rf = 0.8) 
to yield pure 3 (30 %Y). 
Synthesis of 1-O-(3,4,5-trihydroxybenzoyl)-β-D-glucopyranose, βgg, (4). 
Removal of the benzylidene acetal was achieved utilizing perchloric acid adsorbed on 
silica gel, prepared in house and used as described by Misra and Agnihotri. [38, 39]  
After 24 hours, the catalyst was removed by filtration through celite, washed with ACN, 
and then ACN was evaporated in vacuo.  Benzyl ethers were then removed by catalytic 
hydrogenation by dissolving the solid in ethanol and treating with 50 psi H2 at room 
temperature in the presence of 10% Pd/C for four hours.  Catalyst and solvent were 
removed as above and the grayish-white solid obtained was washed for 24 hours with 
CHCl3 to remove any remaining protected intermediates, yielding pure 4 (50 %Y).   
Results and Discussion 
Synthesis of 3,4,5-tris(benzyloxy)benzoic acid (1) and 3,4,5-
tris(benzyloxy)benzoyl chloride (2).  The 1H NMR (DMSO-d6, 400 MHz) and structure 
of 1 is shown in Figure 2.2.  Signals from solvent, water and TMS are colored gray.  The 
purity of the dry recrystallized product was judged to be greater than 99.9%.  The acyl 
chloride 2 was prepared using thionyl chloride, kept under vacuum and used 





glucopyranose (3). The 1H NMR (DMSO-d6, 400 MHz) and structure of 3 is shown in 
Figure 2.3, top panel, with the 5.0-6.0 ppm region expanded below.  Signals from 
solvent, water and ethyl acetate can be seen in the full spectrum and are colored gray.  
The anomeric β proton appears, along with the benzylidene acetal as well as the 
unprotected glucose hydroxyls in the 5.5-5.8 ppm range.  The highly hydrophobic 
compound was easily amenable to silica chromatography, yielding a purity judged to be 
greater than 99.9% after removal of solvent. 
Synthesis of 1-O-(3,4,5-trihydroxybenzoyl)-β-D-glucopyranose, βgg, (4).  The 1H 
NMR (DMSO-d6, 400 MHz) and structure of 4 is shown in Figure 2.3, above, with the 
3.5-6.5 ppm region expanded below.  The anomeric proton doublet (δ 5.5 ppm, J = 7.8 
Hz) is readily distinguishable from the glucose hydroxy proton doublets (δ 5.3, 5.1, and  
Figure 2.2. 1H NMR of 3,4,5-tris(benzyloxy)benzoic acid, 1. (400 MHz, DMSO-d6): δ 




Figure 2.3. 1H NMR of 1-O-(3,4,5-tris(benzyloxy)benzoyl)-4,6-O-benzylidene-β-D-
glucopyranose, 3.  (400 MHz, DMSO-d6) δ ppm 3.46 - 3.55 (m, 2 H) 3.59 - 3.75 (m, 3 
H) 4.23 (dd, J=9.91, 4.64 Hz, 1 H) 5.06 (s, 2 H) 5.20 (s, 4 H) 5.54 (d, J=5.02 Hz, 1 H) 
5.62 (s, 1 H)) 5.72 (d, J=8.0 Hz, 1 H, and d, J=5.8 Hz, 1 H) 7.24 - 7.50 (m, 22 H). 
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5.0 ppm, J = 5.3, 4.8, and 5.5 Hz, respectively) by the coupling constant.  The removal of 
benzyls yielded a highly hydrophilic compound that was easily purified by washing with 
chloroform.  The final compound was deemed to be greater than 99.9% pure before use 
in biochemical assays. 
  
Figure 2.4. 1H NMR of 1-O-(3,4,5-trihydroxybenzoyl)-β-D-glucopyranose, βgg, 4.  
(400 MHz, DMSO-d6) δ ppm 3.11 - 3.30 (m, 4 H) 3.45 (dt, J=11.98, 5.68 Hz, 1 H) 3.65 
(dd, J=10.54, 5.27 Hz, 1 H) 4.57 (t, J=5.90 Hz, 1 H) 5.00 (d, J=5.52 Hz, 1 H) 5.10 (d, 
J=4.77 Hz, 1 H) 5.29 (d, J=5.27 Hz, 1 H) 5.50 (d, J=7.78 Hz, 1 H) 7.00 (s, 2 H) 9.03 (s, 1 




The overall stereospecific synthesis, while not high-yielding (11% from gallic 
acid) was relatively simple, easily accomplished without complicated or dangerous 
apparatus, and readily provided high-purity βgg in mg quantities for biochemical in vitro 
and in vivo analysis.  The bottleneck of synthesis was observed to be the conjugation, 
however the starting materials (gallic acid and glucose) and reagents used were 
inexpensive and provided the β-anomer without chiral purification, so further 
optimization was not found to be necessary. 
 
UV Analysis of Hydrolytic Stability 
Background and Rationale 
Synthesis of new compounds requires at least some minimal attention to bench 
stability, in order to understand how the compound should be handled and stored.  The 
ester linkage of βgg was expected to be labile, as aqueous solutions of esters are subject 
to hydrolysis.  The stability of βgg in four common laboratory storage conditions was 
analyzed using a simple, inexpensive UV method. 
Methods 
General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Spectroscopic analyses 
were performed using a Cary Bio 100 UV/Vis spectrophotometer (Agilent) in quartz 
cuvettes in conjunction Cary WinUV software.   
UV Spectra and Calibration.  In aqueous solution, a substantial difference (about 
16 nm) between the λmax of the weaker n→π* transition of βgg and gallic acid was 
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observed and utilized to quantify the amount of βgg remaining unhydrolyzed in dilute 
aqueous solution.  To generate a calibration curve, solutions were prepared to simulate 
degradation of a dilute (30 µM) aqueous solution of βgg by mixing stock solutions of βgg 
with increasing proportions of gallic acid.  At this concentration, glucose was not found 
to affect the UV spectrum and was not used in calibration standards.  Standards were 
prepared to span the range from pure βgg to pure gallic acid. 
Analysis of Hydrolytic Stability.  In order to assess the shelf stability of prepared 
stock solutions, four mL of a freshly prepared 1 mM βgg solution were divided among 
four identical cryovials and stored in four temperature conditions.  Two solutions were 
frozen (-80 °C and -20 °C), a third was stored at 4 °C, and the fourth was left on the 
laboratory benchtop without temperature control.  Frozen solutions were thawed in a 37 
°C water bath for a few minutes and then held on ice during each analysis, to include the 
effects of multiple freeze-thaws in the experiment.  Solutions were analyzed six times 
throughout the course of a week by taking three 30 µL aliquots and diluting to 1 mL for 
analysis.  UV spectra were collected every 0.1 nm from 260-280 nm and the time-
dependent λmax was recorded. 
Results and Discussion 
UV Spectra and Calibration.  The UV spectra of gallic acid and βgg (200 – 300 
nm) in dilute (30 µM) aqueous solution are shown in Figure 3.5A.  Peaks corresponding 
to the electronic π →π* (~210 nm) and n→π* (262 and 278 nm, respectively) can be 
readily identified.  The difference between the weaker n→π* transition was distinct 
enough to quantify the proportion of hydrolyzed βgg, as shown in Figure 2.5B.  This 




Figure 2.5.  UV analysis of hydrolytic stability.  As an ester, βgg is hydrolytically 
unstable in dilute aqueous solution.  A)  UV spectra of βgg (solid lines) and gallic acid 
(dashed lines) in aqueous solution. A substantial difference between the λmax of the 
weaker n→π* transition of βgg and gallic acid was observed and utilized to quantify the 
amount of βgg remaining unhydrolyzed in dilute aqueous solution.  B)  A sigmoidal 
curve is observed from solutions ranging from pure βgg to pure gallic acid, yielding 
three major linear ranges that can be used for calibration.  C)  Hydrolysis was not 
observed over the course of a week in frozen solutions, after numerous freeze-thaw 
cycles.  Solutions stored at 4 °C or on the laboratory benchtop were not stable to 
hydrolysis.  GraphPad Prism software was used to determine significance by column 
analysis of triplicates using the unpaired, two-tailed student’s t-test.  Error bars indicate 
standard deviation from the mean.  The * symbol denotes a statistically significant 
difference from the measurement at t = 0, where ** indicates P < 0.01, *** indicates P < 
0.001, and ns indicates P > 0.05. 
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was rapid, inexpensive, and suitable for our purposes, i.e. a simple analysis of shelf 
stability in dilute aqueous solution.  The linear range from 2-20% was utilized for the 
interpretation of degradation data over the course of a week.  The best-fit values from 
linear regression (R2 = 0.9987) using GraphPad Prism yielded the following equation 
(error values of the last decimal shown in parentheses):  
λmax = -0.081(2) · (% gallic acid) + 278.4 (1) nm 
indicating the loss of 0.08 nm for every one percent (for the 1 mM solution, this equates 
to 10 µM) of compound hydrolyzed in this range.   
Analysis of Hydrolytic Stability.  The results of the analysis are shown in Figure 
3.5C.   Over the course of a week, no significant differences were observed in the frozen 
solutions after five freeze-thaw cycles, while the λmax of both unfrozen solutions 
decreased.   On day 7, the solution stored at 4 °C had 83 ± 2% (SD) unhydrolyzed βgg 
remaining, while greater than 20% of the benchtop-stored solution was lost to hydrolysis.  
The final concentration could not be quantified without extrapolation from the calibration 
curve, because the observed λmax was lower than that of the 20% gallic acid standard 
solution.   
Conclusions 
After the assay was concluded, it was brought to our attention that oxidation of 
βgg could contribute to the change in the UV signal observed.  However, if this were 
indeed true, the change in UV signal still represented the loss of compound to 
degradation, even if hydrolysis was not the only mechanism. The observation of steady 
degradation in the unfrozen solutions prompted us to utilize caution with room 
temperature solutions, and stock solutions were frozen as single-use aliquots, held on ice 
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during analysis and any remaining aliquot was discarded at the end of the day.  No loss of 
activity was observed in analyses utilizing aliquots stored as long as twelve months and 
handled in this manner. 
 
Potent and Selective Inhibition of Recombinant Human Aldose Reductase 
Background and Rationale 
Given the toxicity associated with nonspecific inhibition of AKR family members 
by ARIs, an ideal pharmacophore need not only to demonstrate bioactivity against the 
target AKR1B1 but at least some selectivity against the other family members.  Utilizing 
purified recombinant human enzymes allows the most realistic in vitro assessment of 
potency and selectivity that can reasonably be obtained. 
Methods 
General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Spectroscopic analyses 
were performed using a Cary Bio 100 UV/Vis spectrophotometer (Agilent) in quartz 
cuvettes in conjunction Cary WinUV software.  Where possible, GraphPad Prism 
software was used to fit normalized data to enzyme inhibition models using nonlinear 
regression (method of least squares).  Recombinant human AKR enzymes were purified 
according to a published procedure as described in Puppala, et al. [15] 
Mechanistic Kinetic Analysis by Inhibition ofXylitol Oxidation.  The activity of 
purified recombinant human AKR1B1 in the direction of substrate oxidation was 
determined with xylitol.  Briefly, the Km for xylitol was determined by combining 
purified enzyme with a solution containing saturating (2.5 mM) NADP+ and varying 
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concentrations of xylitol in 50 mM phosphate buffer, pH 7.0. Solutions were kept on ice 
before mixing, then incubated at 37°C while initial velocities were monitored by 
following the absorbance increase at 340 nm, corresponding to NADP+ reduction 
(stoichiometrically, one mole of NADP+/H is reduced/oxidized to convert one mole of 
substrate).  Kinetic analysis was conducted by comparing the kinetic parameters from 
nonlinear fits of initial velocities in the presence of increasing concentrations of βgg. 
Determination of Selectivity and Potency by Inhibition of Aldehyde Reduction.  
The potency and selectivity of βgg was determined by IC50 assays.  Reactions utilizing 
purified recombinant AKR1B1, AKR1B10, and AKR1A1 were conducted similarly, 
using a saturating concentrations of NADPH (175 µM) and substrate, defined to be at 
least ten times greater than the observed Km for that enzyme-substrate pair, as well as 
physiological hyperglycemic conditions (50 mM glucose).  For reactions with glucose, a 
final concentration of 375 µM NADPH was used to provide saturating conditions for the 
increased concentration of enzyme required to afford measurable reaction rates.  Activity 
was monitored on the same principle, using the absorbance decrease at 340 nm 
corresponding to NADPH oxidation. 
Results and Discussion 
Mechanistic Kinetic Analysis by Inhibition of Xylitol Oxidation.  Using xylitol as 
the substrate, monitoring the rate of NADP+ reduction by AKR1B1 in the presence and 
absence of βgg, we found the inhibition kinetics fit the model of noncompetitive 
inhibition, as shown in Figure 2.6, suggesting that βgg binds both the *E·NADP+ and the 
*E·NADPH complexes with similar affinity (Kii = Kis = 170 ± 20 µM, SEM), according 
to classical kinetics.  As increasing concentrations of βgg were included in the reaction, 
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the apparent Km value did not change, while the Vmax decreased significantly (P = 0.002) 
over the concentration range of 0 – 40 µM.  It is important to note that, while the 
behavior did not fit the competitive inhibition model, for ARIs this does not necessarily 
indicate binding outside of the active site of AKR1B1.  The complexity of the kinetic 
pathway, especially the rate-limiting step of a conformational change involved in 
releasing NADP+, contributes to the discrepancies between observed kinetics for 
inhibitors and structural studies, as discussed by Bohren and Grimshaw: 
The mechanism of inhibition by these compounds has been the subject of 
a great deal of confusion in the past.  Thus, the uncompetitive or 
noncompetitive patterns observed for inhibition of the aldehyde reduction 
reaction by various ARIs has generally led to the conclusion that these 
compounds do not bind at the active site.  Those conclusions disregard the 
possibility that an ARI competing with the alcohol product for binding to 
the *E·NADP+ complex could still bind at the active site and produce the 
observed inhibition patterns.  [12] 
 
However, βgg differs from the traditionally negatively-charged ARIs such as 
sorbinil, in that it is expected to remain neutral at physiological blood pH.  As could be 
expected, these negatively charged inhibitors have been shown to preferentially bind the 
*E·NADP+ complex over the over *E·NADPH complex.  Greater than 99% of the 
enzyme is present as *E·NADP+ after the initial burst of NADPH oxidation that occurs 
before steady-state kinetics are established, but an inhibitor that can bind both complexes 
will affect both the initial burst as well as the steady-state reaction phases.  Interestingly, 
our kinetic observations do not match any of the relevant (Kd > 1 µM) simulations for 
sorbinil, which has been shown to have a 15-fold preference for *E·NADP+.  Combining 
this preference with a 7-fold preference of the enzyme for this conformation in the 
simulations caused the inhibition pattern to appear “nearly competitive” in the direction 
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of xylitol oxidation, and noncompetitive in the direction of xylose reduction, because the 
contribution from Kis became negligible under these conditions. 
Fitting our data (in the direction of xylitol oxidation) to the noncompetitive 
inhibition model yielded pure noncompetitive inhibition, in that the value for Kis was not 
significantly different from that for Kii (200 ± 20 µM and 110 ± 40 µM, respectively).  
This is a key difference between our results and the sorbinil simulations, where Kis << Kii 
and therefore did not contribute to the observed behavior.  Taken together, these results 
Figure 2.6.  Pattern of inhibition of AKR1B1 xylitol oxidation by βgg.  A) Data were 
nonlinearly fit to the Michaelis-Menten model in the absence and presence of 10, 20, and 
40 µM β-glucogallin. B) Lineweaver-Burk plot of the same data, depicting increasing 
slope and y-intercept characteristic of noncompetitive inhibition. C) No significant 
changes were observed in the apparent Km values. D) A decreasing trend was observed in 
the apparent Vmax values, and the differences were found to be statistically significant as 
follows: *indicates P = 0.01, and ***indicates P = 0.0002. All assays were repeated in 
triplicate and error bars represent standard deviation from the mean. GraphPad Prism 
software was used to fit data to the Michaelis-Menten model using nonlinear regression 
(method of least squares) and to determine significance by column analysis of triplicates 
using the unpaired, two-tailed student’s t-test.  Modified from Puppala, et. al. [15] 
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suggest that βgg, as a neutral compound, does not share the preference for *E·NADP+ 
common to the negatively-charged ARIs.  The apparent inhibition mechanism of βgg in 
the direction of substrate reduction could not be accurately determined due to the high 
contribution of noise observed in the control reactions without enzyme. 
Determination of Selectivity and Potency by Inhibition of Aldehyde Reduction.  
Glyceraldehyde was utilized as the substrate for comparison because this substrate is 
readily reduced by all three enzymes analyzed, though the Km values were found to vary.  
At saturating substrate conditions (approximately ten times the Km value), the IC50 
against AKR1B1 was found to be 58 ± 3 µM (SEM), while no significant inhibition was 
observed against AKR1B10 or AKR1A1, even when concentrations exceeded 100 µM, 
as shown in Figure 2.7A.  Interestingly, these two aldehyde reductases do not recognize 
glucose as a substrate and therefore do not participate in the polyol pathway.  Thus, the 
utilization of glucose as a drug moiety may be a major contributing factor in the strong 
selectivity displayed by βgg that is not observed with traditional ARIs.  
AKR1B1 can reduce the open-chain aldose form of glucose, but since the aldose 
form of glucose is quite short-lived in aqueous solutions, its affinity appears poor in 
kinetic experiments.  Though the mechanism was not determined in the direction of 
substrate reduction, when the analysis was conducted using glucose as the substrate, no 
significant difference was observed between reactions where glucose was used at 
saturating (1 M) or physiological hyperglycemic (50 mM) glucose concentrations, as 
shown in Figure 2.7B.   Representing a 20-fold decrease in concentration, 50 mM lies 
near the Km value for glucose.  At this concentration, for a competitive inhibitor, we 




Figure 2.7. AKR inhibition by βgg is potent and selective in vitro.  A) The IC50 was 
determined to be 58 ± 3 µM (SEM) under saturating conditions of the shared substrate 
glyceraldehyde. No significant inhibition against AKR1B10 and AKR1A1 was observed, 
even when inhibitor concentrations exceeded 100 µM.  B) The IC50 was determined to be 
17 ± 1 µM under saturating conditions of the substrate glucose, and did not decrease 
significantly when the concentration of glucose was reduced 20-fold, IC50 = 13 ± 1 µM). 
For all assays, inhibited enzyme activity was normalized to enzyme activity under the 
same conditions in the absence of inhibitor, assays were repeated in triplicate and error 
bars represent standard deviation from the mean. Where possible, GraphPad Prism 
software was used to fit normalized data to the enzyme inhibition model using nonlinear 
regression (method of least squares).  Modified from Puppala, et. al. [15] 
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however this was not observed, adding support to the possibility that βgg binds both the 
*E·NADP+ and *E·NADPH complexes with similar affinity.    
  It is also of interest to note that the potency of βgg was found to be substrate-
dependent, which was not expected.  High concentrations of βgg were not used to fit the 
glyceraldehyde curve as a result of an increasing background signal in the enzyme-free 
control, as shown in Figure 2.8. While some auto-oxidation of NADPH is expected in the 
enzyme-free blank cuvette (represented by a slightly negative observed A/min), using 
increasing concentrations of βgg caused an apparent shift from background oxidation of 
NADPH to background reduction of 
NADP+.  This phenomenon was not 
observed when glucose was used as the 
substrate, nor when βgg and NADPH were 
mixed alone.  Therefore, this most likely 
represents a complex redox reaction 
between βgg, NADPH, and 
glyceraldehyde, stemming from the 
reductive phenols of βgg.  Thus, the 
potency as assessed using glyceraldehyde 
as a substrate likely represents an 
underestimation of potency, and suggests a 
potential explanation of the noise observed 
Figure 2.8. Dependence of autoxidation signal 
on βgg concentration.  When reactions were 
run in the direction of NADPH oxidation, at low 
concentrations, a small decrease in the rate of 
the background (enzyme-free control) signal was 
observed.  As the concentration was increased, 
this background signal (assumed to represent 
oxidation of NADPH) increased to a positive 
value, apparently suggesting the reduction of 
NADP+.  This phenomenon was not observed 
when glucose was used as the substrate, 
suggesting a complex redox reaction involving 
βgg, NADPH, and glyceraldehyde. 
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in mechanistic experiments using the direction of glyceraldehyde reduction.  The IC50 
value determined with saturating concentrations of glucose, 17 ± 1 µM (SEM), may 
therefore reflect the potency of βgg more accurately. 
Conclusions 
While potent inhibition of AKR1B1 is necessary for drug development of an ARI, 
this factor alone has been shown to be insufficient.  Nonselective inhibition of AKR 
family members AKR1B10 and AKR1A1 has resulted in adverse clinical events from 
liver toxicity to death, preventing FDA approval and in the case of the FDA-approved 
tolrestat, prompting a swift market withdrawal.  βgg may differ from traditional ARIs by 
binding the *E·NADPH complex in addition to the *E·NADP+ complex, but the 
evidence for this possibility is not conclusive, nor are the therapeutic implications well 
understood.  Regardless of the inhibition mechanism, the potency and selectivity of βgg 
make it a promising lead compound for nontoxic ARI development. 
 
Efficacy in Cellular and Murine Disease Models 
Background and Rationale 
While it is necessary, and desirable, to explore in vitro methods as much as 
possible, it remains a necessity to demonstrate efficacy within increasingly complex 
biological systems throughout preclinical development.  As complexity increases, the 
consumption of resources increases rapidly, so it is of particular importance to utilize 
these models judiciously to ensure clinical success.  Fortunately, ARIs have been 
explored for decades, and so a number of well-established cellular and animal disease 
models exist for efficacy analysis.  Inflammation is a hallmark in the pathogenesis of 
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diabetic complications, and traditional ARIs have been shown to reduce inflammation 
induced by treatment with lipopolysaccharides (LPS) in cellular and murine models.   
Additionally, the use of a transgenic mouse model of diabetic eye disease, expressing 
human AKR1B1 in the lens, allows us to analyze the human target in a realistic 
biological environment.    
 As part of the preliminary investigation of the HPLC-isolated βgg, its ability to 
prevent accumulation of sorbitol in this murine model of diabetic eyed disease was 
investigated.  The synthesis of βgg provided enough stock compound for further cellular 
and in vivo characterization of its efficacy. 
Methods 
General Information.  Sorbinil ((4S)-6-Fluoro-2,3-dihydro-spiro[4H-1-
benzopyran-4,4′-imidazolidine]-2′,5′-dione) was generously provided by Pfizer Central 
Research (Groton, CT).  Raw264.7 murine macrophages were cultured in complete 
Dulbecco’s Modified Eagle Medium supplemented with 4 mM l-glutamine, 10% (v/v) 
fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin. Cells were 
maintained in a humidified incubator containing 5% carbon dioxide at 37 °C.  The use of 
mice in these studies adheres to policies in the Guide for the Care and Use of Laboratory 
Animals, the United States Public Health Service Policy on the Humane Care and Use of 
Laboratory Animals, and the U.S. Animal Welfare Act.  Approval for the use of mice 
was granted by the University of Colorado-AMC Capitol Institutional Animal Care and 
Use Committee.  
28 
 
Efficacy in Cellular Inflammation Models.  A number of cellular assays were 
conducted to analyze the efficacy of βgg in normalizing LPS-induced inflammation 
markers in Raw264.7 murine macrophages, as described in Chang, et. al.  [40] 
Efficacy in Murine Disease Models.   Transgenic mouse lenses expressing human 
AKR1B1 in the lens were cultured ex-vivo in hyperglycemic conditions, as described in 
Puppala, et. al. [15]  Utilizing an LPS-induced inflammation mouse model of uveitis, a 
single IP injection of βgg was given immediately following LPS injection as described in 
Chang, et. al. [40] 
Results and Discussion 
Efficacy in Cellular Inflammation Models.  The cytotoxicity of βgg was found to 
be quite low.  Negligible cytotoxicity was observed over 24 hours when media was 
supplemented with 50 µM βgg, while supplementation with 100 µM βgg reduced the cell 
population by 16 ± 2%, as determined by a LIVE/DEAD® viability/cytotoxicity Kit 
(Invitrogen, Carlsbad, CA).  As a result, cellular assays were conducted over 24 hours 
using media supplemented with 50 µM βgg.  Addition of βgg to the cellular media 
reduced LPS-induced sorbitol accumulation as well as the production of reactive oxygen 
species (ROS), as shown in Figure 2.9A and B.  Though the antioxidant capacity of βgg 
was not measured directly, as a polyphenol, it is likely that βgg is able to reduce ROS 
directly as well as through the polyol pathway.  
Additionally, βgg was shown to reduce the pro-inflammatory cascade activated in 
macrophages by LPS treatment.  The activation of the pro-inflammatory markers p38 and 
JNK was suppressed by treatment with βgg, demonstrating that pretreatment with βgg 




Figure 2.9.  βgg is effective in LPS-treated macrophage disease models.  A) LPS-
induced sorbitol accumulation in Raw264.7 murine macrophages was reduced by a 24-
hour pretreatment with media supplemented with 50 µM βgg or 10 µM sorbinil. The ** 
symbol indicates a statistically significant difference from cells untreated with LPS (P < 
0.01), and the # indicates a statistically significant difference from cells treated with LPS 
only (P < 0.05).  B) LPS-induced ROS production of macrophages was normalized by 
both treatments.  LPS treatment significantly (denoted by #, P < 0.05) increased ROS 
production, which was found to be at normal levels in both treatment groups.  Error bars 
indicate the standard error of the mean from independent triplicates.  The * symbol 
indicates a statistically significant difference from cells treated with LPS only (P < 0.05).  
C) LPS-induced activation of apoptotic signal proteins is attenuated by both treatments.  
Levels of p-JNK, JNK, and p-p38 were found to be normalized after ARI treatment.  
Modified from Chang, et. al. [40] 
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Efficacy in Murine Disease Models.   When added to ex-vivo culture medium or 
given as an IP injection, βgg is effective in murine models of diabetic complications, as  
shown in Figure 2.10.  In the transgenic mouse model, ex-vivo treatment with 30 µM βgg 
over 72 hours reduced the accumulation of sorbitol by 73% relative to the control lenses, 
as shown in Figure 2.10A.  When given as a single IP injection following the injection of 
LPS, βgg significantly reduced the infiltration of inflammatory cells into both the anterior 




Figure 2.10. βgg is effective in ex-vivo and in-vivo animal disease models. A)  βgg effectively 
reduced sorbitol accumulation in an ex-vivo model of diabetic eye disease. Sorbitol accumulation 
was decreased by 73% in transgenic mouse lenses expressing human AKR1B1 when treated with 
30 µM βgg for 72 hours ex-vivo.  By comparison, 10 µM sorbinil decreased sorbitol accumulation 
95%, while non-transgenic lenses had no detectable sorbitol.  The * symbol denotes a statistically 
significant difference (P<0.05) from untreated transgenic lenses. B) βgg effectively reduced the 
number of inflammatory cells in an LPS-induced in-vivo uveitis model.  IP treatment at 10 mg/kg 
for 24 hours with βgg was as effective as sorbinil in decreasing the number of inflammatory cells 
observed in histological sections of both the anterior and posterior capsules.  The ## symbol 
indicates a statistically significant difference from the AC control (P<0.01) while the ** symbol 
indicates a statistically significant difference from the PC control (P<0.01).  Modified from 




The efficacy in cellular and animal models of diabetic complications has been 
demonstrated to be comparable to that of sorbinil when given at a higher, but less toxic, 
dose.  The successful translation of efficacy from in vitro kinetics to cellular and animal 
disease models adds support to the promise of βgg as a lead compound for nontoxic ARI 
development.  However, the presence of the labile ester was still considered highly 
undesirable for a lead compound, and prevented the use of oral dosing during in vivo 
experiments.  The ester is likely to be rapidly hydrolyzed in an acidic environment such 







SYNTHESIS AND CHARACTERIZATION OF N-[(3,4,5-
TRIHYDROXY)BENZOYL]-β-D-GLUCOPYRANOSYLAMINE AS A STABLE 
PHARMACOPHORE FOR DRUG DESIGN 
 
Development of a Quantitative In Silico Model of ARI Potency 
Background and Rationale 
In order to generate a rational model for drug design using the structure of βgg, 
computational chemistry software was employed.  The 0.85 Å crystal structure of 
AKR1B1 (PDB ID: 2PF8) was analyzed using Discovery Studio v3.1 (Accelrys, San 
Diego, CA).  This software suite contains numerous algorithms that can be used to 
predict binding enthalpies and we sought to explore whether this suite could be used to 
accurately predict in vitro potency of ARIs.  
Methods 
General Information.  Prior to docking, all molecules were typed with the 
CharmM forcefield and protons were corrected for physiological pH.  All protocols 
within the Discovery Studio suite were used with the default settings except as indicated. 
Model Development and Calibration with Aldehyde Substrates.   Previous 
explorations using the rigid docking protocols available within the Discovery Studio suite 
did not provide binding enthalpies that fit our kinetic data, so the Flexible Docking 
protocol was employed despite its prohibitive processor and time consumption.  The 
advantage of this protocol lies in its ability to allow some flexibility of user-selected 
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residues to provide a better approximation of enzyme behavior than is provided by a rigid 
crystal structure.  Residues shown in the literature to have a high degree of flexibility (the 
loop from VAL297 to CYS303, and the nearby residue TYR 309) were classified as 
“High Flex,” while a second group, “Medium Flex” was used to classify residues whose 
literature evidence for flexibility was weaker than that of the first group (THR 113, 
PHE121, PHE122, TRP219).  [41-44] 
Though we wanted to develop a quantitative model of inhibitor potency, our lab 
did not possess a sufficient number of inhibitors to generate distinct calibration and 
validation sets.  However, a wealth of literature describing binding affinities of substrates 
exists, and four aldehyde substrates with affinities ranging from below 1 uM to greater 
than 5 mM, as shown in Figure 1.2, were chosen as a calibration set.  These molecules 
were docked into the active site of 2PF8 with NADPH and binding enthalpies of all 
docked poses were predicted using numerous permutations to test the following 
conditions: the inclusion of water molecules or the use of the Generalized Born (GB), 
Generalized Born with Molecular Volume (GBMV) or Poisson-Boltzmann with Polar 
Surface Area (PBSA) solvent models; the inclusion of the use of Smart Minimizer or 
Conjugate Gradient minimization algorithms, and the number of residues allowed to be 
flexible in the simulation.  Fourteen permutations of these conditions were tested for all 
four substrates and numbered from 1-14 as shown in Table 1.  For each compound, the 
value of the best predicted binding enthalpy was compared against the log-transformed 
Km value using linear regression (method of least squares) to determine if any of the 




Model Validation and Scoring of Inhibitors.  A similar validation set was 
generated from known inhibitors of AKR1B1.  Three published inhibitors, namely 
tolrestat, sorbinil,  and bisdemethoxycurcumin and  as well as βgg, were docked and 
scored using the best protocol (Protocol 5) generated from the calibration test, except that 
both NADPH and NADP+ were used in the docking for comparison.  The inhibitors were 
selected to span a large range of potency (14 nM to 17 µM), as were the substrates used 
for calibration. [7, 15, 45]  This time, predicted binding enthalpies for both conditions 
were compared to the log of the IC50 of each inhibitor using linear regression (method of 
least squares) to determine if the substrate-affinity-calibrated protocol could accurately 
predict inhibitor potency.  This preliminarily validated model was used to explore the 
  
Protocol Flexible Docking Water Solvent Model Minimization
1 High Flex No GB None
2 High Flex No GB Smart Minimizer
3 High Flex No GBMV None
4 High Flex No GBMV Smart Minimizer
5 High Flex No PBSA None
6 High Flex Yes None None
7 High Flex Yes None Smart Minimizer
8 High Flex + Med Flex No GB None
9 High Flex + Med Flex No GB Smart Minimizer
10 High Flex + Med Flex No GBMV None
11 High Flex + Med Flex No GBMV Smart Minimizer
12 High Flex + Med Flex No PBSA None
13 High Flex + Med Flex No GB Conjugate Gradient
14 High Flex + Med Flex No GBMV Conjugate Gradient
Dock Ligand Calculate Binding Energies
Table 1 - Protocols used to generate an in silico model of ARI potency
35 
 
effects of a bioisosteric substitution of an amide for the hydrolytically labile ester of βgg 
on binding within the active site of 2PF8. 
Results and Discussion 
Model Development and Calibration with Aldehyde Substrates.   Of the fourteen 
generated protocols (shown in Table 1), eight were linearly fit and two were found to 
show good agreement (R2 > 0.9) between predicted binding enthalpies and log-
transformed Km values, Protocols 5 and 8, as shown in Table 2.  However, Protocol 8 
achieved this fit while predicting unfavorable binding enthalpies for three of the four 
substrates, so Protocol 5 was chosen for validation. 
 
Protocol R2 slope
IC MG LG XY
1 -0.53 +2.3 +9.5 +12.5 0.88 2.9
2 -2.5 +1.5 +9.1 +9.3 0.79 2.6
3 -15.5 -3.9 +3.1 +3.0 0.79 3.9
4 -5.3 +3.9 +13.2 +65.3 0.87 14.9
5 -24.4 -14.2 -5.3 +0.015 0.93 5.2
6 +80 -178 -164 -179
7 +1135 +141 +106 +160
8 -1.2 +2.8 +7.6 +13.2 0.97 3.1
9 +33000 +2.2 +9.5 +13.9
10 -13.2 +2.6 +4.1 -2.4 0.29 2.1
11 +189000 +5.0 +60.5 -3.0
12 -17.6 +1.6 -3.5 -9 0.12 1.5
13 +2700000 +2.6 +10.1 +12.7
14 +3300000 +2.7 +50 -2.7
Predicted ΔHbinding




Model Validation and Scoring of Inhibitors.  Protocol 5 was preliminarily 
validated by comparing predicted binding enthalpies to inhibitor potencies, with NADP+ 
and NADPH.  Interestingly, when Protocol 5 was executed with NADPH in the docking, 
the linear fit was quite poor, (R2 = 0.22), but when inhibitors were docked into the 
structure containing NADP+, the goodness of fit was found to be 0.83.  This is in 
congruence with what we know about the inhibition mechanism of traditional ARIs and 
provides some additional validation of the preliminary model.  When βgg and the amide-
substituted compound were analyzed with this protocol, little difference was observed 
between the most favorable pose or its predicted binding enthalpy (-13.5 and -14.6 
kcal/mol, respectively), as shown in Figure 3.1. 
Conclusions 
Though the calibration and validation sets utilized were small, they were chosen 
to represent a broad span of affinities and the linear goodness-of-fit values obtained were 
high.  The use of log-transformed IC50 values for linear regression emphasizes the lack of 
sensitivity of the screening tool.  With larger calibration and validation sets, it would be 
possible to identify other quantitative descriptors and use these improve the sensitivity by 
developing a multivariate mathematical model describing the potency of ARIs, and 
utilize this to execute a reliable in silico screen before compounds are even synthesized.  
It was concluded from our investigations using the preliminary model that the 
substitution of an amide should not be expected to alter the potency of AKR1B1 
inhibition, while providing hydrolytic stability more ideal for oral dosing, and so we 
sought to synthesize this compound for analysis. 




Figure 3.1. Computational model of AKR1B1 inhibition.  Discovery Studio 3.1 was 
utilized to explore the binding site of AKR1B1 (PDB ID: 2PF8).  A) AKR1B1 (ribbon) is 
an α/β barrel protein with a central active site.  Active site residues HIS110, TRP111, 
TYR48, as well as NADP+ (orange) are highlighted.  B) βgg docked into the binding site 
of AKR1B1 using Flexible Docking.  Active site residues (magenta), NADPH (cyan) and 
flexible residues (green) are highlighted.  Interactions (pi-pi stacking, orange lines, and 
hydrogen bonds, green dashed lines) are predicted to occur with both the aromatic ring 
and the sugar ring.  The labile ester linkage is not predicted to be a strong contributor to 
binding site interactions.  C) Little difference in binding is predicted by the computational 
model when an amide linkage is substituted for the ester.  Predicted binding enthalpies 




Synthesis of N-[(3,4,5-trihydroxy)benzoyl]-β-D-glucopyranosylamine 
Background and Rationale 
The results of the preliminary in silico model strongly suggested that replacement 
of the ester of βgg with an amide, creating the compound N-[(3,4,5-trihydroxy)benzoyl]-
β-D-glucopyranosylamine, or βga, for simplicity, would preserve its ARI activity while 
eliminating the labile functionality.  Though a relatively simple compound, βga was 
found to be novel and absent in the literature, making it even more attractive as a 
pharmacophore for drug development.  Attempts to synthesize βga by a similar process as 
βgg proved unfruitful so different protecting groups were employed and the amide was 
formed via the Staudinger reaction as shown in Figure 3.2. 
Methods 
General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Structures were 
confirmed by 1H NMR collected using a Bruker Avance III 400 (400 MHz) and analyzed 
using ACD/NMR Processor software (v 12.01, Advanced Chemistry Development, Inc., 
Toronto, Canada). 
Figure 3.2.  Stereospecific synthetic scheme to yield βga from gallic acid.  Phenols 
were masked by acetyl protecting groups and the linkage was formed via a Staudinger 
reaction utilizing acetyl-protected 1-azido-1-deoxy-β-D-glucose.  Acetyls were removed 
by treatment with acetyl chloride in methanol. 
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Synthesis of 3,4,5-triacetoxybenzoyl Chloride (5).  The phenols of gallic acid 
were first masked by acetates and then the acyl chloride 5 was prepared as described 
previously without modification. [35] 
Synthesis of N-[(3,4,5- triacetoxy)benzoyl]-2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosylamine (6).  The amide linkage was formed from azidoglucose as in 
Györgydeák, et al. [46]  To a solution of 50 mg 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl azide in dry DCM was added 140 µL of a 1.0 M solution of PMe3 in 
THF under N2 atm (balloon).  After the evolution of N2 had ceased (10 min), 42.5 mg 5 
were added and stirring continued for 48-72 hours.  The solvent was removed in vacuo 
and the solid obtained was dissolved in DCM and subjected to column chromatography 
(silica, gradient, EtOAc:CHCl3:Hexanes 1:1:1 to EtOAc:CHCl3 2:1, monitored by an in-
line detector at λ = 280 nm) to yield 38.6 mg pure 6 (46 %Y). 
Synthesis of N-[(3,4,5- trihydroxy)benzoyl]-β-D-glucopyranosylamine, βga, (7).  
Acetyls were removed by treatment with acetyl chloride in methanol as described by 
Yeom et. al. [47]  However, in our hands, a greater excess of acetyl chloride was required 
to remove the seven acetyls in a reasonable timeframe.  To a suspension of 11.7 mg 6 in 
methanol, 60 µL acetyl chloride was added in four aliquots.  After 24-72 hours, excess 
methanol and methyl acetate were removed in vacuo.  The solid obtained was washed 
with DCM to yield 5.3 mg of pure 7 (88 %Y).   
Results and Discussion 
Synthesis of 3,4,5-triacetoxybenzoyl Chloride (5).  The 1H NMR (DMSO-d6, 400 
MHz) of 3,4,5-triacetoxybenzoic acid is shown in Figure 3.3.  Signals from solvent and 
water are colored gray.  The recrystallized product was judged to be greater than 99.9% 
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after removal of water.  The acyl chloride 5 was prepared by treatment with thionyl 
chloride and used immediately assuming quantitative yield from the acid. 
Synthesis of of N-[(3,4,5- triacetoxy)benzoyl]-2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosylamine (6).  The 1H NMR (DMSO-d6, 400 MHz) is shown in Figure 3.4.  
Signals from solvent, water, and ethyl acetate are colored gray.  The amide doublet is 
seen at δ 6.97 ppm (J = 8.78 Hz) while the anomeric triplet is observed to overlap with 
another sugar triplet around δ 5.4 ppm.  Despite efforts to remove all solvent before 
spectroscopic analysis, some of the protons are overlapped by ethyl acetate signals.  The 
chromatographically purified product was judged to be greater than 99.9% after removal 
of solvent.   
  
Figure 3.3. 1H NMR of 3,4,5-triacetoxybenzoic acid. (400 MHz, DMSO-d6): δ ppm 2.30 (s, 6 
H) 2.34 (s, 3 H) 7.75 (s, 2 H) 13.33-13.56 (br s, 1 H). 
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Synthesis of N-[(3,4,5- trihydroxy)benzoyl]-β-D-glucopyranosylamine, βga, (7).  
The 1H NMR of crude (DMSO-d6, above) and purified (methanol-d4, below) βga is 
shown in Figure 3.5.  Signals from solvent, water, and DCM are colored gray.  The crude 
product was analyzed in DMSO to verify the removal of acetyls.  In its crude form, the 
Figure 3.4.  1H NMR of N-[(3,4,5- triacetoxy)benzoyl]-2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosylamine, 6. (400 MHz, CHLOROFORM-d) δ ppm 1.60 (s, 3 H) 2.1-2.2 
(m, 9 H) 2.28 - 2.36 (m, 9 H) 3.86 - 3.93 (m, 1 H) 4.33 (dd, J=12.42, 4.14 Hz, 1 H) 5.03 
(t, J=9.66 Hz, 1 H) 5.12 (t, J=9.66 Hz, 1 H) 5.40 (tt, 2 H) 6.97 (d, J=8.78 Hz, 1 H) 7.55 
(s, 2 H). 
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hydroxyl protons of the glucose ring could not readily be identified, but some broadened 
peaks occurred in the region of interest for these protons so the product was washed and 
analyzed in methanol-d4 (δ 3.35, 4.78) to allow analysis of the acetyl methyl region (δ 
2.0-2.5).  After washing with DCM (visible in the lower spectrum, δ 5.5 ppm), the 
product was judged to be greater than 95% pure after removal of solvent, as the use of 
deuterated methanol revealed some minor amounts of acetylated product remaining, seen 
as acetyl methyl protons, δ 2.0 – 2.1 ppm. 
Conclusions 
The overall reaction yield for βga (32% from gallic acid) was greater than that of 
βgg but utilized a fairly expensive sugar reagent.  Synthetic procedures were not 
optimized.  As with βgg, the use of a stereospecific synthesis prevented the necessity of 
chiral purification, allowing for the synthesis of mg quantities of purified drug. 
  
UV Analysis of Stability 
Background and Rationale 
Having demonstrated the instability of the ester linkage, we sought to compare 
this to that the newly synthesized amide derivative, so the UV spectrum of the amide was 
analyzed over the course of a week to determine its stability in dilute aqueous solution. 
Methods 
General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Spectroscopic analyses 
were performed using a Cary Bio 100 UV/Vis spectrophotometer (Agilent) in quartz 




Figure 3.5. 1H NMR of N-[(3,4,5- trihydroxy)benzoyl]-β-D-glucopyranosylamine, 
βga, 7. Crude (above) and purified (below): (400 MHz, DMSO-d6) δ ppm 3.2-3.4 (m, 5 
H) 3.65 (d, J=11.04 Hz, 1 H) 4.88 (t, J=8.91 Hz, 1 H) 6.90 (s, 2 H) 8.39 (d, J=8.53 Hz, 1 
H) 8.70 (s, 1 H) 9.01 (s, 2 H); (400 MHz, METHANOL-d4) δ ppm 3.37 - 3.48 (m, 5 H) 
3.68 - 3.74 (m, 1 H) 3.82 - 3.90 (m, 1 H) 5.05 - 5.10 (d, 1 H) 6.94 (s, 2 H). 
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determine significance by column analysis of triplicates using the unpaired, two-tailed 
student’s t-test. 
Analysis of Stability.  To compare the stability of βgg and βga, a similar assay to 
that of the shelf-stability assay was conducted.  Three 30 µM solutions were prepared, but 
instead, they were stored in a 37 °C water bath.  At each 24 hour interval, 1 mL of each 
solution was removed and analyzed. 
 
Figure 3.6.  UV analysis of hydrolytic stability.  A) UV spectra of βga (solid black 
lines), βgg (solid gray lines) and gallic acid (dashed lines) in aqueous solution.  The 
difference between the λmax of the weaker n→π* transition of βga and gallic acid was less 
than the difference observed with βgg, but remained distinct enough for analysis.  B) As 
an ester, βgg is hydrolytically unstable, while the amide functionality protects βga from 
hydrolysis in dilute aqueous solution.  Hydrolysis of βga was not observed over the 
course of a week at room temperature, while the value of the λmax of βgg solutions was 
again shown to decrease more than 20%.  Error bars represent standard deviation from 
the mean.  GraphPad Prism software was used to determine significance by column 
analysis of triplicates using the unpaired, two-tailed student’s t-test and to analyze data 
using linear regression (method of least squares).  The * symbol indicates a statistically 
significant difference from the reading at t=0.  
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Results and Discussion   
UV Spectra and Calibration.  In aqueous solution, the difference between the λmax 
of the weaker n→π* transition of βga and gallic acid was not as pronounced as that of 
βgg, however it was still distinct enough for analysis, as shown in Figure 3.6A.  No 
differences in λmax were observed in the assay for βga, so no calibration curve was 
utilized for this compound.  A new calibration curve was not generated for βgg.  
 Analysis of Stability.  After four days, a significant (P < 0.05) decrease in the λmax 
of the βgg solution was observed, as shown in Figure 3.6B.  Additionally, the slope of the 
fit line for βgg was found to be significantly different from zero (P < 0.0001) while that 
of βga was not (P > 0.28).  By the end of the week, greater than 20% of the βgg had again 
degraded, while no differences were observed for the βga solutions in this time course.  
Although it might appear that this represents the same degradation rate at room 
temperature and at 37 °C, it is important to note that the room temperature assay was 
conducted using 1 mM solutions, while the solutions in this experiment were prepared at 
30 µM.  The use of percentages in this case obscures the difference observed in the rate at 
room temperature and in the heated water bath. 
Conclusions 
Though the UV assay is not sensitive, as previously discussed, it was suitable for 
the purposes of comparing the rate of simple degradation in aqueous solution. Even when 
conducted at 37 °C, no degradation of βga was observed throughout the week of analysis, 
while a significant (P < 0.05) difference in the λmax was observed for βgg from day 4 
through the end of the experiment, clearly demonstrating the comparative stability of βga 
to degradation in dilute aqueous solution.  As a measure of precaution, βga stock 
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solutions were handled in the same manner as βgg stock solutions, but an additional 
shelf-stability analysis was not conducted. 
 
Potent and Selective Inhibition of Recombinant Human Aldose Reductase 
Background and Rationale 
The computational model suggested that the hydrolytically stable βga would not 
lose potency against the target enzyme AKR1B1.  We determined the potency of βga as 
an ARI as well as its AKR family selectivity by analyzing its inhibitory potential in the 
direction of glyceraldehyde reduction.  
Methods 
General Information.  All chemicals and reagents were purchased from 
commercial sources and used as received except where indicated.  Spectroscopic analyses 
were performed using a Cary Bio 100 UV/Vis spectrophotometer (Agilent) in quartz 
cuvettes in conjunction Cary WinUV software.  Where possible, GraphPad Prism 
software was used to fit normalized data to enzyme inhibition models using nonlinear 
regression (method of least squares). 
Determination of Selectivity and Potency by Inhibition of Aldehyde Reduction.  
The potency and selectivity of βga was determined by IC50 assays.  Reactions utilizing 
purified recombinant AKR1B1, AKR1B10, and AKR1A1 were conducted similarly to 
those for βgg, using increasing concentrations of βga and saturating concentrations of 
NADPH and glyceraldehyde.  Activity was monitored using the absorbance decrease at 




Results and Discussion 
The observed potency of βga agreed strongly with that of βgg, for all three family 
members, as shown in Figure 3.7.  No significant inhibition of AKR1A1 or AKR1B10 
was observed, and the IC50 fit line of inhibition of AKR1B1 by βga was found to be 
strikingly similar to that of βgg.  The IC50 of βga was found to be 42 ± 2 µM, only 
Figure 3.7.  AKR inhibition by βga is as potent and selective as βgg in vitro.  When 
kinetic experiments were repeated with βga (black symbols) no significant difference in 
inhibition from that of βgg (data from Fig 2.7A included in gray for reference) was 
observed.  Potent inhibition of AKR1B1 was observed (IC50 = 42 ± 2 µM, compared to 
IC50 = 58 ± 3 µM for βgg, error values represent SEM).  As with βgg, no significant 
inhibition of the AKR family members AKR1B10 or AKR1A1 was observed, even at 
high inhibitor concentrations.  Inhibited enzyme activity was normalized to enzyme 
activity under the same conditions in the absence of inhibitor, assays were repeated in 
triplicate and error bars represent standard deviation from the mean. Where possible, 
GraphPad Prism software was used to fit normalized data to the enzyme inhibition model 
using nonlinear regression (method of least squares). 
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slightly more potent than βgg.  The maintenance of potency against AKR1B1 is in 
keeping with the preliminarily validated in silico model, which predicted a slightly more 
favorable binding enthalpy.  The maintenance of selectivity is in keeping with the 
hypothesis that utilizing a selective substrate as a drug moiety can infer selectivity to the 
inhibitor.   
Conclusions 
The implications of these results are promising in terms of the development of a 
stable pharmacophore.  The analysis of βga demonstrates that the hydrolytically stable, 
and quite probably orally bioavailable pharmacophore maintains the potency of the 
natural product, βgg.  Additionally, the selectivity against structurally similar family 
members was maintained, providing a stable pharmacophore to use for a thorough 
quantitative structure-activity relationship analysis.  Interestingly, the apparent reduction 
in the enzyme-free reaction controls observed for βgg was not observed for βga, 
suggesting that the apparent antioxidant capacity of βgg may have been diminished by 
the bioisosteric substitution.  Because antioxidation is a synergistic side effect in the 
treatment of diabetic complications, this implication has therapeutic relevance and should 









CHARACTERIZATION OF NEOAMPHIMEDINE AS AN ATP-COMPETITIVE 
TOPOISOMERASE IIα INHIBITOR 
 
Enhanced Inhibition in the Presence of Metnase, a Topoisomerase IIα Activity-
Enhancing Protein 
Background and Rationale 
 Metnase has been shown to resist the action of clinically used TopoIIα poisons by 
interacting with TopoIIα and enhancing its decatenation activity in vitro. In addition, the 
ability of neoamphimedine to inhibit TopoIIα-mediated DNA decatenation has not been 
assessed.  Thus, we conducted decatenation assays with neoamphimedine in the presence 
and absence of an activity enhancing concentration of Metnase. 
Methods 
TopoIIα (TopoGen) was added to 70 ng of kinetoplast DNA (kDNA, TopoGen) 
comprising small interlocked supercoiled circular DNA in reaction buffer (50 mM Tris-
HCl, pH 8.0, 120 mM KCl, 10 mM MgCl2, 0.5 mM DTT, 0.5 mM ATP) in the presence 
or absence of purified recombinant Metnase (200 ng) and increasing concentrations of 
neoamphimedine. Reaction mixtures were incubated at 39 °C for an optimized time of 30 
minutes. The reactions were then separated on a 1% agarose gel containing 0.5 μg/mL 
ethidium bromide with decatenated and catenated DNA markers (TopoGen). 
Fluorescence intensity quantitative analysis was carried out using Quantity One software 
by calculating the percent decatenation by comparing the pixel intensities of both 
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decatenated bands relative to the catenated band.  GraphPad Prism was used to analyze 
inhibition curves generated from the mean decatenation values determined in this way 
from three independent gels. 
Results and Discussion 
The results of the DNA decatenation assay are shown in Figure 4.1. 
Neoamphimedine inhibits TopoIIα-dependent decatenation at low concentrations with 
Figure 4.1. Neoamphimedine inhibits Metnase-enhanced TopoIIα-dependent DNA 
decatenation in vitro. A) Representative TopoIIα-decatenation gels treated with 
neoamphimedine as indicated and B) repeated in the presence of Metnase. DNA markers 
are denoted as M1 (decatenated, linear and circular) and M2 (catenated). C) Inhibition 
curves generated from decatenation assays.  Error bars represent standard error of the 
mean from triplicate assays. The concentration giving 50% inhibition is observed near 2 
µM without Metnase, while it occurred below the lowest tested concentration when 200 
ng Metnase was included.  Modified from Ponder, et. al. 
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50% inhibition occurring around 2 μM.  These data agree with the reported cell based 
antitumor activity of neoamphimedine (IC50 values ranging from 1 - 6 μM) in various 
human tumor cell lines. [28, 48]  In the presence of Metnase, the DNA decatenation 
activity of TopoIIα is enhanced, yet so is the apparent potency of neoamphimedine, with 
greater than 50% inhibition observed at the lowest concentration tested, 0.5 μM.  This 
suggests Metnase-bound TopoIIα has a greater affinity for neoamphimedine than free 
TopoIIα. 
Conclusions 
This finding suggested that neoamphimedine could overcome drug resistance 
resulting from protein-TopoIIα complexes such as Metnase-bound TopoIIα.  This result 
is especially significant because Metnase has been shown to block the action of 
traditional TopoIIα poisons in both cell-based and in vitro decatenation assays.   
 
Inhibition of the Invasive Potential of Colorectal Cancer Cells Grown as 
Multicellular Tumor Spheroids 
Background and Rationale 
Neoamphimedine is a novel TopoIIα inhibitor, in that does not stabilize the 
cleaved complex, nor does it cause significant DNA strand breaks or intercalate into 
DNA at concentrations below 100 μM. Neoamphimedine is not a substrate for the P-
glycoprotein xenobiotic transport pump, and it has been shown to be as efficacious as 
current clinical TopoIIα poisons both in vitro as an inhibitor of TopoIIα and in vivo as an 
antitumor agent.  Still, its anti-metastatic efficacy has not been assessed, primarily 
because neoamphimedine is too powerfully cytotoxic in traditional 2D cell culture for 
52 
 
such analysis.  However, we found that growing multicellular tumor spheroids (MCTSs) 
of colorectal cancer cell lines allowed us to treat with neoamphimedine for several days, 
allowing for the investigation of phenotypes such as loss of invasive potential.   
Methods 
General Information.  For traditional and MCTS culture, low-passage colorectal 
cancer cell lines DLD-1 and HCT-116 cells were cultured in Dulbelcco’s Modified Eagle 
Medium containing phenol red supplemented with 10% fetal bovine serum.  Cells were 
kept in a humidified incubator maintained at 37 °C and 5% CO2. Growth-Factor Reduced 
BD Matrigel Basement Membrane Matrix (BD Biosciences, San Jose, CA) was thawed 
and divided into aliquots to prevent numerous freeze-thaw cycles.  All other cell culture 
reagents were obtained from commercial sources and used as received.  Neoamphimedine 
was synthesized according to literature procedures, prepared as a 5 mM stock in DMSO 
and frozen at -20 °C until needed for analysis.  Spheroids cultured in hanging drop plates 
were photographed using a Nikon Eclipse TE 300 in conjunction with NIS Elements 
imaging software (v 4.13, Melville, NY).  Diameters were measured using the n point 
circle function by defining the perimeter of the spheroid using at least ten points. 
MCTS Culture in a 3D Hanging Drop Format.  Subconfluent colorectal cancer 
cells cultured in monolayers were trypsinized, washed, and live cells were counted using 
a hemocytometer after staining with Trypan Blue.  DLD-1 cells were seeded at 5,000 
cells per well and HCT-116 cells were seeded at 10,000 cells per well into the wells of a 
96-well Perfecta3D hanging drop plates (3D Biomatrix, Ann Arbor, MI) using 20 µL 
drops.  After spheroid formation (24 hours), 10 µL culture medium containing Growth-
Factor Reduced Matrigel was added (final concentration: 5% v/v) gently, so as not to 
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disturb loose aggregates.  After compact spheroids were formed (48 hr), media was added 
to increase the volume to 35 µL (assuming a 10 µL loss to evaporation in the hanging 
drop every two days, as described in the accompanying protocol).  Using this method, 
greater than 90% single spheroid formation could be reproducibly acquired for both 
DLD-1 and HCT-116 cells.  Media was maintained at this volume by addition of 10 µL 
every two days until treated with neoamphimedine.  Evaporation was slowed by the 
addition of agarose to the external plate chambers and media to the unused external wells.   
 For analysis in the invasion assay, sixty spheroids of each cell line were seeded.  
After Matrigel addition, wells containing formed, compact, single spheroids, were 
divided into drug or vehicle treatment groups by plate row or column, whichever 
provided an equivalent number of spheroids to both groups.  Spheroids were 
photographed and diameters were measured every two days (alternating media addition). 
Neoamphimedine (final concentration: 10 µM) or DMSO was added to the culture 
medium on the day following a measured diameter average greater than 500 µM, to allow 
for differentiation of the cellular layers in the spheroid.  Spheroids were harvested 72 
hours after treatment with drug or vehicle.  Additional neoamphimedine was not included 
in the media after the first dose, and drop volume was maintained by the addition of 5 µL 
daily to minimize volume fluctuations, such that the absolute concentration of 
neoamphimedine was maintained at 10 ± 2 µM. 
Invasive Potential as Determined by a Boyden Chamber Assay.  After 72-hour 
exposure to neoamphimedine or DMSO, spheroids from different groups were harvested, 
pooled, and trypsinized to single-cell suspensions, according to a literature procedure.  
Cells were washed three times using serum-starved media (0.1% fetal bovine serum), 
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counted in triplicate using a hemocytometer and plated into prepared, Growth-Factor 
Reduced Matrigel-coated Boyden chambers at 200,000 cells per chamber.  Normal media 
(10% fetal bovine serum) was used in the lower chamber as a chemoattractant.  After 72 
hours, cells remaining above the membrane were swabbed out.  The chambers were 
washed three times with phosphate buffered saline following fixation in methanol for 1 
minute.  Fixed invaded cells were stained with DAPI (4',6-diamidino-2-phenylindole, 5 
µg/mL in phosphate buffered saline), and visualized under a fluorescent microscope.  
Five fields (center, N, S, E, and W) from each of two invasion chambers were 
photographed and invaded cells were counted using MetaMorph (Molecular Devices, 
Sunnyvale, CA) image analysis software. 
Results and Discussion 
MCTS Culture in a 3D Hanging Drop Format.  The morphology of initial 
aggregate and MCTS formation for DLD-1 and HCT-116 is shown in Figure 4.2.  Using 
the optimized spheroid formation protocol of seeding wells with 20 µL, after 24 hours, 
DLD-1 formed compact single spheroids before the addition of Matrigel, while HCT-116 
cells had only loosely aggregated by this timepoint.  The addition of the Matrigel 
basement membrane matrix induced compact spheroid formation within 24 hours in 
HCT-116 cells, and did not affect the morphology of the already compact DLD-1 
MCTSs. 
The growth of CRC MCTSs treated with drug or vehicle is shown in Figure 4.3.  
Interestingly, neither the growth nor the morphology, as observed with the light 
microscope, of MCTSs was found to vary between the two treatment groups over the 72-




Figure 4.2. Morphology of Aggregation and Spheroid Formation in CRC MCTSs.  
After 24 hours, DLD-1 MCTSs (seeded at 5000 cells/well) had formed compact single 
spheroids without the addition of Matrigel.  By contrast, HCT-116 cells (seeded at 10000 
cells/well) aggregated but Matrigel treatment was necessary to induce the formatin of 
compact spheroids.  Bar indicates 500 µm. 
Figure 4.3. Growth of CRC MCTSs in a hanging drop format.  A) Growth of DLD-1 
and B) Growth of HCT-116 MCTSs.  Diameters were measured every other day, 
beginning 24 hours after Matrigel addition (black arrows).  After spheroid diameters were 
observed to exceed 500 µm, neoamphimedine (10 µM) or vehicle (0.2% DMSO) was 
added to the hanging drop culture medium (gray arrows).  No differences in diameter or 
morphology as visualized under the light microscope were observed throughout the 72 
hour between the drug and vehicle treated MCTSs.  Dotted lines have been added to help 
visualize growth rates.  Error bars represent standard error of the mean (N ≥ 25). 
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cells were harvested and counted for plating in the subsequent invasion assay it was 
found that the neoamphimedine-treated spheroids yielded 40-50% fewer cells per 
spheroid, and thus the number of cells harvested from the neoamphimedine-treated 
MCTSs became the limiting factor when plating the cells in the Boyden chambers. 
We utilized this platform to analyze the efficacy of exposure to a single dose of 
neoamphimedine for 72 hours on the effect of invasive potential as measured by a 
Boyden chamber assay.  The Boyden assay relies upon fixing, staining and counting the 
cells adhered to the underside of a membrane, after permeating through a basement 
membrane matrix as a response to fetal bovine serum as a chemoattractant.  This 
Figure 4.4. Boyden chamber invasion assay optimization.  When HCT-116 cells 
were grown in traditional 2D monolayer culture, a substantial amount of invasion was 
observed after a 24 hour incubation in the Boyden chamber using 10% FBS as the 
attractant.  However, when the experiment was repeated using cells harvested from 
drug- or vehicle-treated MCTSs, the invasion observed was barely measurable.  Error 
bars represent standard error of the mean from optimization assays. 
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emphasizes the utility of this platform for analyzing the effects of compounds too 
cytotoxic for analysis in traditional monolayer culture. 
Invasive Potential as Determined by a Boyden Chamber Assay.  Initial invasion 
optimization assays were misleading when conducted using cells from 2D culture, as 
shown in Figure 4.4.  Using HCT-116 cells, substantial (greater than 100 invaded 
cells/field) was observed.  When this timepoint was used for cells harvested from drug or 
vehicle-treated MCTSs, the invasion was immeasurably low, as most microscopic fields 
contained no invaded cells at all.  Although the  neoamphimedine treatment for 72 hours 
in the MCTS culture significantly reduced the ability of both DLD-1 and HCT-116 cells 
Figure 4.5. Boyden chamber invasion assays conducted using cells harvested from 
MCTSs. Invaded cells per microscopic field from neoamphimedine (+) and vehicle (-) 
treated cells cultured in the Boyden chamber for the indicated time using A) DLD-1 and 
B) HCT-116 cells.  Box-and-whisker plots depict range, standard deviation, and median. 
Significant differences in invasiveness could not be discerned between drug- and vehicle-
treated MCTSs of either CRC cell line after a 48 hour incubation, as the invasion 
observed in all of these groups was too low for good quantification.  C) After 72 hours, 
the invasive potential of vehicle-treated DLD-1 and HCT-116 cells was reduced by more 
than 60% for both CRC cell lines.  This reduction was statistically significant, as 
determined by the student’s two-tailed t-test, using Welch’s correction for unequal 
variances (* indicates P < 0.05, *** indicates P < 0.001). 
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to invade, after 72 hours the invasive phenotype recovered in both cell types and a 
significant difference was observed between the cells from drug and vehicle treated 
spheroids, as shown in Figure 4.5.  The number of invaded cells observed was reduced by 
more than 60% for both DLD-1 and HCT-116 cells, suggesting cytotoxicity similar to 
that found previously. 
Conclusions 
These results are of particular significance because they demonstrate the potency 
of neoamphimedine in a model of metastasis.  It is important to recognize that a single 
dose of 10 µM neoamphimedine prevented the recovery of the metastatic phenotype in 
both cell lines, which occurred more than 48 hours after removal of drug (and vehicle) 
from the culture medium. This emphasizes the potency of neoamphimedine’s inhibition 
of TopoIIα in a tumor environment, where it has already been demonstrated to be 
cytotoxic, but not anti-metastatic. 
 
Inhibition of Topoisomerase IIα 
Background and Rationale 
Since neoamphimedine does not act as a TopoIIα poison it seemed likely that it 
binds TopoIIα at a different site than classical TopoIIα poisons, which bind near the 
DNA binding site. Given that TopoIIα must hydrolyze ATP during catalytic function we 
hypothesized that Metnase-TopoIIα interactions do not obstruct the N-terminal ATPase 
sites of TopoIIα and that neoamphimedine binds to this site, circumventing Metnase-
mediated MDR.  To analyze this possiblity we first measured TopoIIα dependent ATP 
hydrolysis in the presence of supercoiled DNA, recombinant human TopoIIα and varying 
concentrations of neoamphimedine.  To determine if neoamphimedine could reasonably 
59 
 
be expected to fit within the ATP-binding site of TopoIIα, we explored the crystal 
structure of the N-terminal ATPase domain using the Discovery Studio (Accelrys) 
software suite. 
Methods 
Steady-State Inhibition Kinetics.  An ATP hydrolysis assay that quantifies 
inorganic phosphate through the formation of a high molar absorptivity complex with 
malachite green and molybdate was adapted for use in 384-well plates, with a total 
reaction volume of 15 μL [16]. We first utilized this assay to determine the Km of 
TopoIIα for its natural substrate, ATP, using concentrations ranging from 62.5 to 1600 
μM. To measure the apparent Km and Vmax in the presence of inhibitor, the same reactions 
were repeated in the presence of 2, 5, and 10 μM neoamphimedine. Absorbance at 620 
nm was measured using a SpectraMax Plus plate reader in conjunction with SoftMax Pro 
software.   Experiments were repeated in duplicate and GraphPad Prism software was 
used to perform non-linear fits (method of least squares) to the Michaelis-Menten kinetic 
inhibition model. 
Structural Analysis of the ATP-Binding Site of TopoIIα.  All Discovery Studio 
protocol settings were left at default except where indicated.  The CHARMm force field 
was applied to the 1.87 Å crystal structure of the ATPase domain of human TopoIIα 
(PDB: 1ZXM). Water and ANP molecules were removed and residues were corrected for 
physiological pH (7.4).  Both homodimeric ATPase sites were defined to include residues 
within a 12 Å radius subset encompassing the bound ATP mimic within both the A and B 
chain of the crystal structure.  The LibDock protocol was used for the molecular docking 
of neoamphimedine into the defined ATP-binding sites of TopoIIα using 100 hotspots.  
60 
 
Binding energies of all generated poses were calculated using the Generalized Born 
implicit solvent model, assuming a solvent dielectric constant of 80.  The pose with the 
most favorable predicted binding energy was utilized for analysis. 
Results and Discussion 
Kinetic Inhibition Analysis.  The results of the inhibition analysis are shown in 
Fig. 4.6.  Although the quantification of inorganic phosphate was found to be highly 
sensitive, the production of inorganic phosphate in the reactions was highly variable.  
Still, a linear (R2 = 0.94) and significant (P = 0.01) increase in the apparent Km could be 
observed from including 0 – 10 μM neoamphimedine, in agreement with the competitive 
inhibition model and binding in the ATPase sites of TopoIIα. 
Structural Analysis of the ATP-Binding Site of TopoIIα.  The XRAY crystal 
structure (PDB ID: 1ZXM) of the homodimeric N-terminal ATPase domain with 
neoamphimedine docked into the ATPase sites is shown in Fig. 4.7A.  Nearby residues 
Figure 4.6.  Inhibition Pattern of TopoIIα ATPase activity by Neoamphimedine. A) 
Enzyme velocity curves were non-linearly fit to the Michaeles-Menten inhibition model 
for analysis.  B) A linear (R2 = 0.94) increase in apparent Km is observed over the range 
of 0 to 10 μM concentrations of neoamphimedine.  The apparent Km increased from from 
390 ± 50 to 790 ± 120 μM, in agreement with a competitive pattern of inhibition.  
Modified from Ponder, et. al. 
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are shown with neoamphimedine in the A chain site (Figure 4.7B), while the pose in the 
B chain site is shown with a cutaway of the solvent-accessible surface (Figure 4.7C). 
Neoamphimedine docked similarly into both homodimeric ATPase sites of 
1ZXM.  Though protein structures in reality are invariably more dynamic than crystal 
structures, this particular structure was crystallized with a non-hydrolysable ATP mimic, 
phosphoaminophosphonic acid-adenylate ester (ANP).  This compound, which differs 
from ATP by linking the third phosphate through an amine, was crystallized in both 
ATPase sites, giving us the most relevant possible conformation of the residues within 
these sites.  The in silico model suggested that neoamphimedine would bind the ATPase 
sites favorably (predicted ΔHbinding = -271 and 277 kcal/mol for the A and B dimers of 
1ZXM, respectively), primarily due to hydrophobic and pi-cation interactions (Figures B 
and C), rather than electrostatic attraction, which made an unfavorable (+5 kcal/mol) 
contribution to the predicted complex energy.   
Conclusions 
Together, these results do not negate the possibility that neoamphimedine’s novel 
activity stems from binding competitively within the ATPase sites of TopoIIα, preventing 
it from performing any tasks dependent on the fuel of ATP hydrolysis.  Structural studies, 
such as the resolution of a crystal structure with bound neoamphimedine are necessary to 





Figure 4.7. Neoamphimedine docked into the N-terminal ATPase domain of 
TopoIIα.  A) When the XRAY crystal structure of TopoIIα’s ATP-hydrolyzing domain 
was explored using the Discovery Studio software suite, it was observed that the structure 
of neoamphimedine fit snugly into both ATP pockets.  The homodimeric chains of the N-
terminal domain of TopoIIα are shown as ribbons, with neoamphimedine molecules 
highlighted as yellow stick figures.  B) Neoamphimedine was predicted to have strong pi-
cation attractions (orange) to the magnesium ion (green), when docked in the A chain 
site. C) Neoamphimedine showed the same attractions in the B-chain site, depicted as a 
solvent-accessible surface colored by polarity.  The majority of the exposed pocket 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
β-Glucogallin: A Selective Inhibitor of Human Aldose Reductase Isolated from 
Emblica Officinalis 
The overall stereospecific synthesis, while not high-yielding (11% from gallic 
acid) was relatively simple, easily accomplished without complicated or dangerous 
apparatus, and readily provided high-purity βgg in mg quantities for biochemical in vitro 
and in vivo analysis.  The bottleneck of synthesis was observed to be the conjugation, 
however the starting materials (gallic acid and glucose) and reagents used were 
inexpensive and provided the β-anomer without chiral purification, so further 
optimization was not found to be necessary. 
While potent inhibition of AKR1B1 is necessary for drug development of an ARI, 
this factor alone has been shown to be insufficient.  Nonselective inhibition of AKR 
family members AKR1B10 and AKR1A1 has resulted in adverse clinical events from 
liver toxicity to death, preventing FDA approval and in the case of the FDA-approved 
tolrestat, prompting a swift market withdrawal.  βgg may differ from traditional ARIs by 
binding the *E·NADPH complex in addition to the *E·NADP+ complex, but the 
evidence for this possibility is not conclusive, nor are the therapeutic implications well 
understood.  The efficacy in cellular and animal models of diabetic complications has 
been demonstrated to be comparable to that of sorbinil when given at a higher, but less 
toxic, dose.  The successful translation of efficacy from in vitro kinetics to cellular and 
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animal disease models adds support to the promise of βgg as a lead compound for 
nontoxic ARI development.   
A UV assay was utilized to conduct assays of stability in aqueous solution.  
Though this assay was not sensitive, it was suitable for the purposes of comparing the 
rate of simple hydrolysis between the two compounds. Even when conducted at 37 °C, no 
hydrolysis of βga was observed throughout the week of analysis, while a significant 
difference in the λmax was observed for βgg from day 4 through the end of the 
experiment, clearly demonstrating the comparative stability of βga to degradation in 
dilute aqueous solution.   
Additionally, a preliminary computational model of ARI potency was developed.  
Though the calibration and validation sets utilized were small, they were chosen to 
represent a broad span of affinities and the linear goodness-of-fit values obtained were 
high.  The use of log-transformed IC50 values for linear regression emphasizes the lack of 
sensitivity of the screening tool.  With larger calibration and validation sets, it would be 
possible to identify other quantitative descriptors and use these improve the sensitivity by 
developing a multivariate mathematical model describing the potency of ARIs, and 
utilize this to execute a reliable in silico screen before compounds are even synthesized.  
The implications of the kinetic results are promising in terms of the development 
of a hydrolytically stable pharmacophore.  The analysis of βga demonstrates that the 
hydrolytically stable, and quite probably substantially more orally bioavailable 
pharmacophore maintains the potency of the natural product, βgg.  Additionally, the 
selectivity against structurally similar family members was maintained, providing a stable 
pharmacophore to use for a thorough quantitative structure activity analysis.  
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Interestingly, the apparent reduction in the enzyme-free reaction controls observed for 
βgg was not observed for βga, suggesting that the apparent antioxidant capacity of βgg 
may have been diminished by the bioisosteric substitution.  Because reduction of ROS is 
a synergistic side effect in the treatment of diabetic complications, this implication has 
therapeutic relevance and should be investigated. 
 
Neoamphimedine May Exhibit Novel Topoisomerase IIα Inhibitory Activity 
through ATP-Competitive Inhibition 
These results are of particular significance because they demonstrate the potency 
of neoamphimedine in a model of metastasis.  It is important to recognize that a single 
dose of 10 µM neoamphimedine prevented the recovery of the metastatic phenotype in 
both cell lines, which occurred more than 48 hours after removal of drug (and vehicle) 
from the culture medium.  This emphasizes the potency of neoamphimedine’s inhibition 
of TopoIIα in a tumor environment, where its potency as a cytotoxic, but not anti-
metastatic agent has already been demonstrated.  
Although the quantification of inorganic phosphate was found to be highly 
sensitive, the production of inorganic phosphate in the reactions was highly variable.  
Still, a linear and significant increase in the apparent Km could be observed, in agreement 
with the competitive inhibition model and binding in the ATPase sites of TopoIIα.  
Neoamphimedine docked similarly into both homodimeric ATPase sites of 1ZXM.  
Though protein structures in reality are invariably more dynamic than crystal structures, 
this particular structure was crystallized with a non-hydrolysable ATP mimic, 
phosphoaminophosphonic acid-adenylate ester (ANP).  This compound, which differs 
66 
 
from ATP by linking the third phosphate through an amine, was crystallized in both 
ATPase sites, giving us the most relevant possible conformation of the residues within 
these sites.  The in silico model suggested that neoamphimedine would bind the ATPase 
sites favorably, primarily due to hydrophobic and pi-cation interactions.  Together, these 
results do not negate the possibility that neoamphimedine’s novel activity stems from 
binding competitively within the ATPase sites of TopoIIα, preventing it from performing 
any tasks dependent on the fuel of ATP hydrolysis.  Structural studies, such as the 
resolution of an XRAY crystal structure with bound neoamphimedine, are necessary to 
provide conclusive evidence. 
 
Drug Discovery and Development from Natural Products: Taking Advantage of 
Evolutionarily-Designed Scaffolds 
The work presented in this thesis clearly demonstrates the advantage of 
combining the power of evolution to design a scaffold with the implementation of in 
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